Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The DDAH-ADMA-NOS pathway.

James M Leiper1

  • 1Centre for Clinical Pharmacology, British Heart Foundation Laboratories, Division of Medicine, University College London, UK. james.leiper@ucl.ac.uk

Therapeutic Drug Monitoring
|January 13, 2006
PubMed
Summary
This summary is machine-generated.

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS) that regulates nitric oxide generation. This article explores ADMA

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolomic profiling of amines in sepsis predicts changes in NOS canonical pathways.

PloS one·2017
Same author

Overexpression of GTP cyclohydrolase 1 feedback regulatory protein is protective in a murine model of septic shock.

Shock (Augusta, Ga.)·2014
Same author

Response to letters regarding article, "unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine".

Circulation·2014
Same author

The role of ATM in response to metformin treatment and activation of AMPK.

Nature genetics·2012
Same author

Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas.

The Journal of pathology·2011
Same author

Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.

Kidney international·2009
Same journal

Mass Spectrometric Characterization of Flucloxacillin Binding to Serum Albumin in Hospitalized Patients With Hypoalbuminemia: An Observational Pilot Study.

Therapeutic drug monitoring·2026
Same journal

Therapeutic Drug Monitoring-Driven Prediction of Cyclosporine-Associated Liver Injury in Pediatric Thalassemia After Hematopoietic Stem Cell Transplantation.

Therapeutic drug monitoring·2026
Same journal

Donor-derived Cell-free DNA Does Not Improve the Detection of Acute Kidney Allograft Rejection Beyond Urinary CXCL9 and CXCL10.

Therapeutic drug monitoring·2026
Same journal

A Novel Dosing Strategy for Tacrolimus in Lung Transplant Recipients: Integrating Machine Learning with Population Pharmacokinetic Analysis.

Therapeutic drug monitoring·2026
Same journal

Recommendations for Assessing Methodological Quality in Systematic Reviews of Population Pharmacokinetic Models: A Systematic Review.

Therapeutic drug monitoring·2026
Same journal

Wide-Range Quantification of Belumosudil in Patients with Chronic Graft-Versus-Host Disease by High-Performance Liquid Chromatography.

Therapeutic drug monitoring·2026
See all related articles

Area of Science:

  • Biochemistry
  • Physiology
  • Pathophysiology

Background:

  • Endogenous inhibitors of nitric oxide synthase (NOS) are increasingly recognized.
  • Asymmetric dimethylarginine (ADMA) is a key endogenous NOS inhibitor.

Purpose of the Study:

  • To describe the biology of ADMA.
  • To discuss the implications of ADMA in cardiovascular physiology and pathophysiology.

Main Methods:

  • Literature review of ADMA biology and function.
  • Analysis of ADMA's role in cardiovascular disease states.

Main Results:

  • ADMA plays a significant role in regulating nitric oxide (NO) generation.
  • Dysregulation of ADMA contributes to cardiovascular pathophysiology.

Conclusions:

  • ADMA is a critical regulator of NO bioavailability.
  • Understanding ADMA biology is essential for cardiovascular research and treatment.